Treatment of SLE lupus-prone mice with an anti-IL-21 blocking antibody reduced titers of autoantibodies, delayed progression of glomerulonephritis and diminished renal-infiltrating Tfh and Th1 cells, whilst improving overall survival (81). Here, IL21 is linked to systemic lupus erythematosus.